Cubosomes for topical delivery of the antimicrobial peptide LL-37

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 134, Issue , 2019, Pages 60-67

  Boge, Lukas ^a,b   Hallstensson, Karin ^a   Ringstad, Lovisa ^a   Johansson, Jenny ^a   Andersson, Therese ^a   Davoudi, Mina ^c   Larsson, Per Tomas ^d   Mahlapuu, Margit ^e,f   Håkansson, Joakim ^a   Andersson, Martin ^b  

^a RISE RESEARCH INSTITUTES OF SWEDEN   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d INNVENTIA AB   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antimicrobial peptide; Cubosome; Infection; LL 37; Proteolysis; Skin irritation; Topical delivery

Indexed keywords

ALCOHOL; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CUBOSOME; DRUG CARRIER; FLUORESCAMINE; GLYCEROL OLEATE; HYDROTROPE; NANOPARTICLE; UNCLASSIFIED DRUG; ACYLGLYCEROL; ANTIINFECTIVE AGENT; ANTIMICROBIAL PEPTIDE LL-37; CATHELICIDIN;

ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ADSORPTION; DRUG RELEASE; EPIDERMIS; EX VIVO STUDY; GEL; IN VITRO STUDY; LIQUID CRYSTAL; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PROTEIN DEGRADATION; SKIN INFECTION; SKIN IRRITATION; STAPHYLOCOCCUS INFECTION; TOPICAL DRUG ADMINISTRATION; ULTRASOUND; WOUND INFECTION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; ESCHERICHIA COLI; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PIG; PROCEDURES; SMALL ANGLE SCATTERING; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TOXICITY TESTING; TREATMENT OUTCOME; X RAY DIFFRACTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS; CATHELICIDINS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; EPIDERMIS; ESCHERICHIA COLI; ETHANOL; GLYCERIDES; HUMANS; LIQUID CRYSTALS; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; SCATTERING, SMALL ANGLE; SKIN IRRITANCY TESTS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; SWINE; TREATMENT OUTCOME; WOUND INFECTION; X-RAY DIFFRACTION;

EID: 85056876558     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2018.11.009     Document Type: Article

References (59)

1. WHO, Antimicrobial resistance: global report on surveillance, 2014.
2. Czaplewski, L., et al. Review: alternatives to antibiotics—a pipeline portfolio review. Lancet. Infect. Dis. 16 (2016), 239–251.
3. Moet, G.J., et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn. Microbiol. Infect. Dis. 57:1 (2007), 7–13.
4. Church, D., et al. Burn wound infections. Clin. Microbiol. Rev. 19:2 (2006), 403–434.
5. Giacometti, A., et al. Epidemiology and microbiology of surgical wound infections. J. Clin. Microbiol. 38:2 (2000), 918–922.
6. Lowy, F.D., Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111:9 (2003), 1265–1273.
7. Leaper, D.J., et al. Surgical site infection - a European perspective of incidence and economic burden. Int. Wound J. 1:4 (2004), 247–273.
8. Dryden, M.S., Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 65:suppl_3 (2010), iii35–iii44.
9. Pasupuleti, M., Schmidtchen, A., Malmsten, M., Antimicrobial peptides: key components of the innate immune system. Crit. Rev. Biotechnol. 32:2 (2012), 143–171.
10. Hancock, R.E.W., Sahl, H.-G., Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:12 (2006), 1551–1557.
11. Schmidtchen, A., et al. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J. Biol. Chem. 284:26 (2009), 17584–17594.
12. Eckert, R., Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol. 6:6 (2011), 635–651.
13. Mahlapuu, M., et al. Antimicrobial peptides: an emerging category of therapeutic agents. Frontiers Cell. Infect. Microbiol., 6, 2016.
14. Nordström, R., Malmsten, M., Delivery systems for antimicrobial peptides. Adv. Colloid Interface Sci. 242 (2017), 17–34.
15. Angelova, A., et al. Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc. Chem. Res. 44:2 (2010), 147–156.
16. Angelova, A., et al. Advances in structural design of lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor agents. Adv. Colloid Interface Sci. 249 (2017), 331–345.
17. Matougui, N., et al. Lipid-based nanoformulations for peptide delivery. Int. J. Pharm. 502:1–2 (2016), 80–97.
18. Mulet, X., Boyd, B.J., Drummond, C.J., Advances in drug delivery and medical imaging using colloidal lyotropic liquid crystalline dispersions. J. Colloid Interface Sci. 393 (2013), 1–20.
19. Boge, L., et al. Lipid-based liquid crystals as carriers for antimicrobial peptides: phase behavior and antimicrobial effect. Langmuir 32:17 (2016), 4217–4228.
20. Boge, L., et al. Cubosomes post-loaded with antimicrobial peptides: characterization, bactericidal effect and proteolytic stability. Int. J. Pharm. 526:1–2 (2017), 400–412.
21. Boge, L., et al. Freeze-dried and re-hydrated liquid crystalline nanoparticles stabilized with disaccharides for drug-delivery of the plectasin derivative AP114 antimicrobial peptide. J. Colloid Interface Sci. 522 (2018), 126–135.
22. Meikle, T.G., et al. Incorporation of antimicrobial peptides in nanostructured lipid membrane mimetic bilayer cubosomes. Colloids Surf., B 152 (2017), 143–151.
23. Gontsarik, M., et al. Antimicrobial peptide-driven colloidal transformations in liquid-crystalline nanocarriers. J. Phys. Chem. Lett. 7:17 (2016), 3482–3486.
24. Lozeau, L.D., Rolle, M.W., Camesano, T.A., A QCM-D study of the concentration- and time-dependent interactions of human LL37 with model mammalian lipid bilayers. Colloids Surf., B. 167 (2018), 229–238.
25. Ramos, R., et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides 32:7 (2011), 1469–1476.
26. Strömstedt, A.A., et al. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by Using Variants of EFK17, an Internal Segment of LL-37. Antimicrob. Agents Chemother. 53:2 (2009), 593–602.
27. Gronberg, A., et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 22:5 (2014), 613–621.
28. Shahmiri, M., et al. Membrane core-specific antimicrobial action of cathelicidin LL-37 peptide switches between pore and nanofibre formation. Sci. Rep., 6, 2016, 38184.
29. Sood, R., et al. Binding of LL-37 to model biomembranes: insight into target vs host cell recognition. Biochim. Biophys. Acta (BBA) – Biomembr. 1778:4 (2008), 983–996.
30. Vandamme, D., et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 280:1 (2012), 22–35.
31. Jain, S., et al. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J. Pharm. Sci. 106:2 (2017), 423–445.
32. Sala, M., et al. Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications. Int. J. Pharm. 535:1 (2018), 1–17.
33. Zhai, Y., Zhai, G., Advances in lipid-based colloid systems as drug carrier for topic delivery. J. Control. Release 193 (2014), 90–99.
34. Lopes, L., et al. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm. Res. 23:6 (2006), 1332–1342.
35. Lopes, L.B., Speretta, F.F.F., Bentley, M.V.L.B., Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. Eur. J. Pharm. Sci. 32:3 (2007), 209–215.
36. Rattanapak, T., et al. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J. Pharm. Pharmacol. 64:11 (2012), 1560–1569.
37. Esposito, E., et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm. Res. 22:12 (2005), 2163–2173.
38. Seo, S.R., et al. In vivo hair growth-promoting efficacies of herbal extracts and their cubosomal suspensions. J. Ind. Eng. Chem. 19:4 (2013), 1331–1339.
39. Bazylińska, U., et al. Polymer-free cubosomes for simultaneous bioimaging and photodynamic action of photosensitizers in melanoma skin cancer cells. J. Colloid Interface Sci. 522 (2018), 163–173.
40. Kulkarni, C.V., et al. Monoolein: a magic lipid?. Phys. Chem. Chem. Phys.: PCCP, 13(8), 2011, 3004.
41. U.S. Food and Drug Administration (FDA), Inactive Ingredient Search for Approved Drug Products, [cited 2018 2018-10-11]; (Available from: < https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm>).
42. Barauskas, J., et al. Cubic phase nanoparticles (cubosome): principles for controlling size, structure, and stability. Langmuir 21:6 (2005), 2569–2577.
43. Spicer, P., Cubosome processing: industrial nanoparticle technology development. Chem. Eng. Res. Des. 83:11 (2005), 1283–1286.
44. Spicer, P.T., et al. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir 17:19 (2001), 5748–5756.
45. Hyde, S.T., Identification of Lyotropic Liquid crystalline Mesophases. Holmberg, K., (eds.) Handbook of Applied Surface and Colloid Chemistry, 2001, John Wiley & Sons, Ltd., 299–332.
46. OECD, Test No. 439: In Vitro Skin Irritation - Reconstructed Human Epidermis Test Method. 2013, OECD Publishing.
47. Björn, C., et al. Anti-infectious and anti-inflammatory effects of peptide fragments sequentially derived from the antimicrobial peptide centrocin 1 isolated from the green sea urchin Strongylocentrotus droebachiensis. AMB Express 2 (2012), 67–167.
48. Bjorn, C., et al. Anti-infective efficacy of the lactoferrin-derived antimicrobial peptide HLR1r. Peptides 81 (2016), 21–28.
49. Myhrman, E., et al. The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections. Appl. Microbiol. Biotechnol. 97:7 (2013), 3085–3096.
50. Xhindoli, D., et al. The human cathelicidin LL-37–A pore-forming antibacterial peptide and host-cell modulator. Biochim. Biophys. Acta 1858:3 (2016), 546–566.
51. Zhang, X., et al. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery. Biochim. Biophys. Acta 1798:12 (2010), 2201–2208.
52. Demurtas, D., et al. Direct visualization of dispersed lipid bicontinuous cubic phases by cryo-electron tomography. Nat. Commun., 6, 2015, 8915.
53. Coates, A.R.M., Halls, G., Hu, Y., Novel classes of antibiotics or more of the same?. Br. J. Pharmacol. 163:1 (2011), 184–194.
54. Patzelt, A., et al. Selective follicular targeting by modification of the particle sizes. J. Control. Release 150:1 (2011), 45–48.
55. Oren, Z., et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 341:Pt 3 (1999), 501–513.
56. Barauskas, J., et al. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes. Int. J. Pharm. 391:1–2 (2010), 284–291.
57. Milak, S., Zimmer, A., Glycerol monooleate liquid crystalline phases used in drug delivery systems. Int. J. Pharm. 478:2 (2015), 569–587.
58. Leesajakul, W., et al. Interaction of cubosomes with plasma components resulting in the destabilization of cubosomes in plasma. Colloids Surf., B 34:4 (2004), 253–258.
59. Gupta, A., Landis, R.F., Rotello, V.M., Nanoparticle-based antimicrobials: surface functionality is critical. F1000 Res., 5, 2016, F1000 (Faculty Rev-364).